ABBV · News · 20260817N
Acquisition / Partnership / Divestiture
AbbVie Inc. · 2026-08-17 · Importance 47 · Surprise 60 · In source text
AbbVie’s acquisition of Apogee Therapeutics is expected to close, after which Apogee will become an indirect wholly owned subsidiary of AbbVie. Apogee reported $1.3 billion in cash in the second quarter of 2026, providing a substantial funding base for the acquired business. Apogee’s directors are scheduled to resign following completion of the transaction, while its zumilokibart program remains a major investment focus.
Key facts
- Exchange Traded Concepts LLC increased its stake in AbbVie Inc. by 204.3% in Q2, bringing its total holdings to 105,544 shares valued at $26.6 million. source
- TradingView reported that Apogee Therapeutics' directors are set to resign following the closing of the AbbVie acquisition, which will make Apogee an indirect wholly owned subsidiary of AbbVie. source
- Bellecapital International Ltd. increased its stake in AbbVie Inc. by 13% during the second quarter, acquiring an additional 8,728 shares, bringing its total holdings to 75,615 shares valued at approximately $19.0 million. source
- Institutional investors and hedge funds collectively own 70.23% of AbbVie. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| assets | positive | probable | — | TradingView reported that Apogee Therapeutics' directors are set to resign following the closing of the AbbVie acquisition, which will… |